LEDT and Idebenone treatment modulate autophagy and improve regenerative capacity in the dystrophic muscle through an AMPK-pathway
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0300006 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Heloina Nathalliê Mariano da Silva und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil. Hauptthemen laut MEDLINE: Muscle, Skeletal, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Purpose
Considering the difficulties and challenges in Duchenne muscular dystrophy (DMD) treatment, such as the adverse effects of glucocorticoids, which are the main medical prescription used by dystrophic patients, new treatment concepts for dystrophic therapy are very necessary. Thus, in this study, we explore the effects of photobiomodulation (PBM; a non-invasive therapy) and Idebenone (IDE) treatment (a potent antioxidant), applied alone or in association, in dystrophic muscle cells and the quadriceps muscle, with special focus on autophagy and regenerative pathways.
Methods
For the in vitro studies, the dystrophic primary muscle cells received 0.5J LEDT and 0.06μM IDE; and for the in vivo studies, the dystrophic quadriceps muscle received 3J LEDT and the mdx mice were treated with 200mg/kg IDE.
Results
LEDT and IDE treatment modulate autophagy by increasing autophagy markers (SQSTM1/p62, Beclin and Parkin) and signaling pathways (AMPK and TGF-β). Concomitantly, the treatments prevented muscle degeneration by reducing the number of IgG-positive fibers and the fibers with a central nucleus; decreasing the fibrotic area; up-regulating the myogenin and MCH-slow levels; and down-regulating the MyoD and MHC-fast levels.
Conclusion
These results suggest that LEDT and IDE treatments enhance autophagy and prevented muscle degeneration in the dystrophic muscle of the experimental model. These findings illustrate the potential efficacy of LEDT and IDE treatment as an alternative therapy focused on muscle recovery in the dystrophic patient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil.
ORCID-Profile: Elaine Minatel
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Silva, H. N. M. D., Fernandes, E. M., Pereira, V. A., Mizobuti, D. S., Covatti, C., Rocha, G. L. D., & Minatel, E. (2024). LEDT and Idebenone treatment modulate autophagy and improve regenerative capacity in the dystrophic muscle through an AMPK-pathway. PLOS ONE. https://doi.org/10.1371/journal.pone.0300006
Vancouver
Silva HNMD, Fernandes EM, Pereira VA, Mizobuti DS, Covatti C, Rocha GLD, et al. LEDT and Idebenone treatment modulate autophagy and improve regenerative capacity in the dystrophic muscle through an AMPK-pathway. PLOS ONE. 2024. doi:10.1371/journal.pone.0300006
BibTeX
@article{Silva2024,
author = {Silva, Heloina Nathalliê Mariano da and Fernandes, Evelyn Mendes and Pereira, Valéria Andrade and Mizobuti, Daniela Sayuri and Covatti, Caroline and Rocha, Guilherme Luiz da and Minatel, Elaine},
title = {LEDT and Idebenone treatment modulate autophagy and improve regenerative capacity in the dystrophic muscle through an AMPK-pathway},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0300006}
}
EUVIMED